NASDAQ:FATE - Fate Therapeutics Stock Price, News & Analysis

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.04. The biopharmaceutical company earned $2.80 million during the quarter, compared to analyst estimates of $1.09 million. Fate Therapeutics had a negative return on equity of 50.05% and a negative net margin of 934.70%. Fate Therapeutics's quarterly revenue was up 180.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.37) earnings per share. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Fate Therapeutics.

15 brokerages have issued 1-year target prices for Fate Therapeutics' stock. Their predictions range from $17.00 to $32.00. On average, they anticipate Fate Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Media coverage about FATE stock has been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Repligen (RGEN), argenx (ARGX), Moderna (MRNA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX) and Coherus Biosciences (CHRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Tandem Diabetes Care (TNDM).

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.92%), Victory Capital Management Inc. (4.48%), Vanguard Group Inc. (4.17%), Artal Group S.A. (2.30%), Price T Rowe Associates Inc. MD (1.82%) and Arch Venture Corp (1.49%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Artal Group S.A., Eversept Partners LP, Lisanti Capital Growth LLC, Price T Rowe Associates Inc. MD, Westfield Capital Management Co. LP, Alps Advisors Inc. and Bank of New York Mellon Corp. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Wells Fargo & Company MN, Nuveen Asset Management LLC and ARK Investment Management LLC. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $18.57.

Fate Therapeutics has a market capitalization of $1.21 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]